The TandemHeart®, percutaneous transseptal left ventricular assist device: a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experience
- 1 November 2008
- journal article
- clinical trial
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 4 (3) , 331-337
- https://doi.org/10.4244/eijv4i3a60
Abstract
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Keywords
This publication has 18 references indexed in Scilit:
- Validation of the 2000 Bernstein-Parsonnet Score Versus the EuroSCORE as a Prognostic Tool in Cardiac SurgeryThe Annals of Thoracic Surgery, 2006
- Five-Year Outcomes After Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel DiseaseJournal of the American College of Cardiology, 2005
- Assessment of validity for EuroSCORE risk stratification systemScandinavian Cardiovascular Journal, 2005
- Validation of Mayo clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registryJournal of the American College of Cardiology, 2003
- Risk score for percutaneous coronary intervention: forewarned is forearmed**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.Journal of the American College of Cardiology, 2003
- Correlates of procedural complications and a simple integer risk score for percutaneous coronary interventionJournal of the American College of Cardiology, 2002
- Risk stratification analysis of operative mortality in heart and thoracic aorta surgery: comparison between Parsonnet and EuroSCORE additive modelEuropean Journal of Cardio-Thoracic Surgery, 2001
- Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel DiseaseNew England Journal of Medicine, 2001
- Frontiers in Interventional CardiologyCirculation, 1998
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988